---
document_datetime: 2024-05-02 09:40:33
document_pages: 24
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/volibris-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: volibris-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 16.1809926
conversion_datetime: 2025-12-19 11:16:00.55593
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Volibris

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                           | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                    |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------|
| II/0067              | To update sections 4.8 and 5.1 of the SmPC following the assessment of Art 46 procedure (EMEA/H/C/000839) based on final results from study AMB114588; this is an open-label, long term extension study for treatment of pulmonary arterial hypertension in paediatric patients aged 8 years up | 14/03/2024                          |                                             | SmPC, Annex II and PL            | Please refer to the Scientific Summary \"h-839-AR-II-67-en\" |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The

CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                   | to 18 years who have participated in AMB112529 and in whom continued treatment with ambrisentan is desired. In addition, the MAH took the opportunity to implement minor editorial changes to Annex II and to the Package Leaflet. C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH   |            |            |                                  |                                                                  |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------|
| PSUSA/129/2 02306 | Periodic Safety Update EU Single assessment - ambrisentan                                                                                                                                                                                                                                                                                                                                                                                                                   | 08/02/2024 | n/a        |                                  | PRAC Recommendation - maintenance                                |
| IB/0066           | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                         | 31/03/2022 | n/a        |                                  |                                                                  |
| IB/0065           | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                | 02/12/2021 | n/a        |                                  |                                                                  |
| X/0061/G          | This was an application for a group of variations. Annex I_2.(c) Change or addition of a new strength/potency A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                 | 22/07/2021 | 22/09/2021 | SmPC, Annex II, Labelling and PL | Please refer to Scientific Discussion Volibris-H-C-839-X- 0061-G |

<div style=\"page-break-after: always\"></div>

|                   | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                         |            |            |                 |                                                           |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------------------------------|
| IA/0064           | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                          | 19/02/2021 | 22/09/2021 | Annex II and PL |                                                           |
| PSUSA/129/2 02006 | Periodic Safety Update EU Single assessment - ambrisentan                                                                                                                                                                              | 11/02/2021 | n/a        |                 | PRAC Recommendation - maintenance                         |
| IAIN/0063         | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 21/01/2021 | n/a        |                 |                                                           |
| IB/0060           | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                           | 15/05/2020 | n/a        |                 |                                                           |
| IA/0059           | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                       | 11/09/2019 | n/a        |                 |                                                           |
| IA/0058           | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                   | 30/08/2019 | n/a        |                 |                                                           |
| II/0055           | Submission of an updated Risk Management Plan                                                                                                                                                                                          | 14/02/2019 | 21/10/2019 | Annex II        | Removal of the provision of the educational materials for |

<div style=\"page-break-after: always\"></div>

|             | (RMP) version 8.1 in order to remove the provision of the educational materials for healthcare professionals given the availability of the SmPC and the experience of using ambrisentan and to revise the educational materials for patients as requested by the PRAC in the PSUR procedure PSUSA/00000129/201706. The Annex II of the product information is updated accordingly. In addition, the MAH also took the opportunity to update the Annex II as requested by the Portuguese Agency following the approval of the last update to the educational materials (risks of decreases in haemoglobin or haematocrit, renal impairment, peripheral oedema and fluid retention, and hypersensitivity reaction) and to correct typographical errors. The requested variation proposed amendments to the Annex II and to the Risk Management Plan (RMP). C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH   |            |            |                 | healthcare professionals given the availability of the SmPC and the experience of using ambrisentan as requested by the PRAC in the PSUR procedure PSUSA/00000129/201706. Patients continue to be informed with a clear and concise message on the risk of 'hepatotoxicity' and 'teratogenicity' through additional risk minimisation measures, mainly with the patient reminder card. The Annex II of the product information is updated accordingly.   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0057/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.c.1 - Change to importer, batch release                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 31/01/2019 | 21/10/2019 | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|                   | arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0054           | Update of sections 4.2 and 5.3 of the SmPC based on results of a juvenile nonclinical toxicology study. The Risk Management Plan version 7.9 (in version 2 of the RMP template) has been updated accordingly. In addition, the Marketing authorisation holder (MAH) corrected typographical errors including the rash frequency in section 4.8 of the SmPC and the date of renewal; and introduced minor update in the braille section. Moreover, the MAH took the opportunity to combine version of the SmPCs for the different strengths. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 31/10/2018 | 21/10/2019 | SmPC, Labelling and PL | In juvenile rats administered ambrisentan orally once daily during postnatal day 7 to 26, 36 or 62, a decrease in brain weight (-3% to -8%) with no morphologic or neurobehavioral changes occurred after breathing sounds, apnoea and hypoxia were observed. These effects occurred at exposures approximately 1.8 to 7 times human paediatric exposures at 10 mg (age 9 to 15 years), based on AUC. The clinical relevance of this finding to the paediatric population is not fully understood. |
| T/0056            | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 12/10/2018 | 29/10/2018 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| PSUSA/129/2 01706 | Periodic Safety Update EU Single assessment - ambrisentan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 11/01/2018 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IB/0053/G         | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 05/12/2017 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                   | re-test period/storage period supported by real time data B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data   |            |            |                        |                                   |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| IB/0051           | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                          | 26/04/2017 | 19/04/2018 | SmPC, Labelling and PL |                                   |
| PSUSA/129/2 01606 | Periodic Safety Update EU Single assessment - ambrisentan                                                                                                                                                                          | 12/01/2017 | n/a        |                        | PRAC Recommendation - maintenance |
| IAIN/0050         | B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer                     | 12/12/2016 | n/a        |                        |                                   |
| IB/0049           | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                       | 03/10/2016 | n/a        |                        |                                   |
| II/0047/G         | This was an application for a group of variations. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                   | 14/07/2016 | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

|                   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                                  |                                                                 |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------|
| PSUSA/129/2 01506 | Periodic Safety Update EU Single assessment - ambrisentan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 14/01/2016 | n/a        |                                  | PRAC Recommendation - maintenance                               |
| II/0041           | Extension of indication for the treatment of pulmonary arterial hypertension (PAH), in adult patients of WHO Functional Class (FC) II to III including use in combination treatment; as a consequence sections 4.1, 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC are updated. A warning related to the increase in peripheral oedema and anemia with the combination therapy is introduced in section 4.4. Section 4.8 is updated accordingly to include updated frequencies of ADRs observed in the AMBITION study and with a new ADR introduced (sudden hearing loss) in case of use in combination therapy. The Package Leaflet is updated in accordance. In addition, the annex II is updated with a minor change in the key messages to healthcare professionals and also in line with the latest version of the QRD template. A change to the list of local representatives is also introduced in the Package Leaflet. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or | 22/10/2015 | 20/11/2015 | SmPC, Annex II, Labelling and PL | Please refer to Scientific Discussion Volibris-H-C-839-II- 0041 |

<div style=\"page-break-after: always\"></div>

| IA/0046   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                     | 19/11/2015   | n/a        |                       |     |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|-----|
| II/0039   | The MAH has provided the clinical study report for the post-authorisation safety study 'AMB110094 (VOLT)', and as a consequence minor editorial changes have been implemented in secion 4.4 of the SmPC. An updated RMP version 6.4 was agreed during the procedure. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                               | 19/11/2015   | 27/10/2016 | SmPC, Annex II and PL | N/A |
| IA/0045/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 24/09/2015   | n/a        |                       |     |
| IB/0043   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 25/08/2015   | n/a        |                       |     |

<div style=\"page-break-after: always\"></div>

|             | changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                           |            |            |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0042/G | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch | 15/07/2015 | 20/11/2015 | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| PSUV/0040   | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                   | 09/01/2015 | n/a        |                 | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0038     | Update of SmPC section 4.8 to add the ADRs 'vision blurred' and 'visual impairment'. The Package Leaflet has been updated accordingly. In addition, the applicant took the opportunity to make editorial changes to the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                               | 25/09/2014 | 27/05/2015 | SmPC and PL     | As part of this application, the MAH provided a cumulative review as requested following the assessment of the last PSURs. This cumulative review included a discussion regarding spontaneous safety reports, data of clinical trials, literature review and disproportionality analysis scores using data from the FDA Spontaneous Reporting System (SRS)/Adverse Event Reporting System (AERS) database. In the light of all safety data provided, there is enough evidence to support a possible causal relationship between ambrisentan and the ADRs 'vision blurred' and 'visual impairment'. Therefore, these ADRs have been included in the SmPC and Package Leaflet for ambrisentan. The safety data provided as part of the cumulative review |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |                       | do not change the benefit/ risk balance for ambrisentan, which remains positive for the authorised indication(s).                                                                                                                                                                                                                                                   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUV/0037 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 10/07/2014 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                   |
| II/0035/G | This was an application for a group of variations. Update to sections 4.5 and 5.2 of the SmPC in light of new information contained from the study 'Effect of Ambrisentan on Human Hepatic Uptake and Efflux Transporters'. The MAH also proposed corrections to the wording of the rat embryofoetal study results in section 5.3 of the SmPC and made an editorial change in section 4.2. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 26/06/2014 | 27/05/2015 | SmPC, Annex II and PL | In this variation additional information on pharmacokinetic interactions of ambrisentan indicating that the medicine is unlikely to affect transport of other molecules into the liver was included in the product information. Moreover, further clarification was added to the section of the product information with the results from the non-clinical studies. |
| N/0034    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 19/02/2014 | 23/04/2014 | PL                    |                                                                                                                                                                                                                                                                                                                                                                     |
| IB/0036   | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 12/02/2014 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                     |
| II/0033   | Submission of a non-clinical final study report as part of the paediatric requirements.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 23/01/2014 | n/a        |                       | In the European Union, Volibris is the approved for pulmonary arterial hypertension (PAH) treatment in adults. No dose recommendations are available for children and                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|           | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority   |            |            |                                  | adolescents for the time being. A Paediatric Investigation Plan (PIP) was submitted and agreed with the Paediatric Committee (PDCO) (EMA Decision P/0062/2013 issued 26th March 2013). This PIP refers to the condition 'Primary and secondary pulmonary hypertension' and includes the following non-clinical measures: • Two-week juvenile animal study to determine tolerability and toxicokinetics of ambrisentan. • Eight-week juvenile animal study to determine oral toxicology and toxicokinetic of ambrisentan including an 8 weeks recovery period. The objective of this variation is to submit the study report of the two-week juvenile animal study to determine the tolerability and toxicokinetics of ambrisentan. The CHMP considers that the results from the tolerability and toxicokinetics study of ambrisentan in juvenile rats do not alter the overall benefit risk assessment of Volibris for   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUV/0032 | Periodic Safety Update                                                                                                                          | 09/01/2014 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IG/0279   | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                      | 18/04/2013 | 23/04/2014 | SmPC, Labelling and PL           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| R/0030    | Renewal of the marketing authorisation.                                                                                                         | 15/11/2012 | 14/01/2013 | SmPC, Annex II, Labelling and PL | Based on the CHMP review of the available information and on the basis of a re-evaluation of the benefit risk balance, the CHMP is of the opinion that the quality, safety and efficacy of Volirbis continues to be adequately and sufficiently demonstrated and therefore considers that the benefit risk profile of Volibris continues to be favourable in the treatment of adult patients with pulmonary arterial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |             | hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity. The CHMP is also of the opinion that the renewal can be granted with unlimited validity.                                     |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0026   | Update of sections 4.3 and 5.1 of the SmPC after the assessment of the 7th PSUR, in order to add a contraindication in idiopathic pulmonary fibrosis (IPF) with or without secondary pulmonary hypertension, and to add information about a clinical study in patients with IPF. The package leaflet has been updated accordingly. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 21/06/2012 | 03/08/2012 | SmPC        | For further information please refer to the scientific conclusion: H-000474-VAR-II-0026-en.                                                                                                                                  |
| IB/0029/G | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                       | 16/07/2012 | n/a        |             |                                                                                                                                                                                                                              |
| II/0025   | Update of section 4.8 of the SmPC following assessment of the 7th PSUR, to include the term \"epistaxis\". The Package Leaflet is updated in accordance.                                                                                                                                                                                                                                                                                                                                    | 19/04/2012 | 25/05/2012 | SmPC and PL | In the assessment of the 7th PSUR (period covered: 15.12.10 - 14.06.11) the MAH was requested to include ' epistaxis' as an ADR in section 4.8 of the SmPC, under the category of frequency 'common', based on the frequency |

<div style=\"page-break-after: always\"></div>

|           | C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH                                                                                                                                                                                                                                                                           |            |            |             | observed in two controlled- clinical trials.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0024   | Update of section 4.8 of the SmPC in order to add the terms \"asthenia\" and \"fatigue\" following the evaluation of the 6th PSUR in which a cumulative review of cases of asthenia/fatigue was requested by the CHMP. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 15/03/2012 | 13/04/2012 | SmPC and PL | A cumulative review of cases of asthenia/fatigue was requested by the CHMP after the assessment of the 6th PSUR. This review was submitted by the MAH on 24 October 2011. Following this review, the MAH concluded that the data regarding time to onset and recovery after discontinuation of ambrisentan therapy in those cases of asthenia and fatigue occurring within one month of starting ambrisentan, as well as the recurrence of the asthenic condition upon restart of ambrisentan therapy in some cases support at least a reasonable possibility of a causal relationship to ambrisentan. In view of this the MAH updated section 4.8 of the SmPC to include asthenia and fatigue as undesirable effects with a frequency of 'common'. The package leaflet was updated accordingly. |
| IG/0150/G | This was an application for a group of variations. C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                                                                                                                                                            | 05/04/2012 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| II/0021   | Update of sections 4.4, 4.6 and 5.1 of the SmPC in order to update the warning regarding reductions in haemoglobin concentrations, to include updated information regarding male fertility, and to include data from the ambrisentan ARIES-E study (A long term study of ambrisentan in pulmonary arterial hypertension subjects having completed AMB-320 OR AMB-321). C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data   | 16/02/2012   | 21/03/2012   | SmPC   | Ambrisentan, a selective ETA receptor antagonist, has shown to be effective in idiopathic PAH (IPAH) and in PAH associated with connective tissue disease (PAH-CTD). In order to provide more information on the long-term effects of ambrisentan, patients in studies AMB-320 and AMB-321 had the option of continuing (or starting, if on placebo) ambrisentan treatment through a long-term extension study, AMB-320/321-E (ARIES E). The available information provided suggests a substantial improvement in survival at 1, 2 and 3 years in the PAH population compared to that which would ordinarily be anticipated. The observed probability of survival for subjects receiving Volibris (combined Volibris dose group) at 1, 2 and 3 years was 93%, 85% and 79% respectively. In addition, descriptive data on exposure and main primary endpoint in the ARIES E study (incidence and severity of adverse events) has also been included in section 5.1 of the SmPC. The distinction between IPAH and PAH-CTD is not considered necessary. Regarding safety, the ADRs identified in the ARIES-E study are consistent with the known safety profile of ambrisentan and/or the natural history and the seriousness of the disease. This study has provided evidence of long-term persistence in haemoglobin reductions, information which has been included in section 4.4 of the SmPC. This study has also provided data on 2-year risk of developing ALT/AST elevations >x3ULN, long-term persistence in BP decreases that have been included in section 4.4 of the SmPC. Lastly, although no clear evidence of a detrimental   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |             | was found in ARIES-E study, chronic administration of ambrisentan was associated with changes in markers of spermatogenesis, and this has been reflected in section 4.6 of the SmPC.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0019   | Update of sections 4.4 and 4.8 of the SmPC, following the assessment of the 6th PSUR, in order to include information on anaemia requiring transfusion, and to reorganize the adverse reactions and frequency categories into a single table. The Package Leaflet was updated in accordance. In addition, the MAH took the opportunity to update section 6 of the Package Leaflet in order to include the full address of the Manufacturer. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the | 16/02/2012 | 21/03/2012 | SmPC and PL | Following the assessment of 6th PSUR in May 2011, the MAH was requested to submit a type II variation to include information on the potential severity of anaemia and cases of anaemia requiring transfusion in the SmPC. A cumulative review of patients who developed anaemia that required transfusion was submitted leading to changes in section 4.4 of the SmPC. A footnote with this information was also added to the table of adverse drug reactions in section 4.8. The package leaflet was updated accordingly. In this variation the MAH also reviewed section 4.8 of the SmPC following the Guideline on SmPC (rev.2, Sep. 2009) recommendations, and merged into a single table all adverse drug reactions (from clinical studies and from spontaneous reporting) with their respective frequency categories. |
| IAIN/0027 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 14/03/2012 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IB/0023/G | This was an application for a group of variations. B.I.c.2.z - Change in the specification parameters and/or limits of the immediate packaging of the AS - Other variation B.I.c.1.a - Change in immediate packaging of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 20/01/2012 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|         | - Qualitative and/or quantitative composition                                                                                                                                                                                                                                                                                                                                      |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0020 | Update of section 5.3 of the SmPC in order to update the preclinical safety information further to a review of rat carcinogenicity data, together with a correction to the information on the rat embryofoetal development. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 17/11/2011 | 14/12/2011 | SmPC | Carcinogenicity studies in both mice and rats were previously submitted and reviewed as part of the Marketing Authorisation Application for Volibris. In the original rat study, histological analysis revealed a number of non-neoplastic findings in the heart, spleen, kidney, nasal cavity, lung, testes and dental dysplasia of the incisors. Haematological correlates associated with the nasal cavity findings included increased red cell parameters. These changes are considered to be directly or indirectly related to the pharmacological activity of ambrisentan. The NOAEL for non-neoplastic findings was lower than the low dose of 10 mg/kg/day, corresponding to <34.8 and <24.6 µg.h/mL in males and females, respectively. The conclusion of this study was that there were no treatment-related increases in the incidence of tumours. Upon further review of the data from this rat study by the Japanese Health Authorities, a statistically significant increase in the incidence of mammary gland fibroadenoma was identified in males treated at the highest dose level (mean dietary dose of 42 mg/kg/day). As a result of this assessment, the MAH proposed new wording for Section 5.3 Preclinical safety data. The MAH also made a correction in section 5.3 of the SmPC as the statement referring to the rat embryofoetal study results was incomplete. After reviewing the data submitted the CHMP considers that the proposed amendments to the SmPC do not alter the overall favourable benefit risk assessment of ambrisentan |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |                 | for the treatment of pulmonary arterial hypertension.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0017 | Following the CHMP assessment on cumulative overview of the hepatic safety profile (FUM 021) MAH has applied to update sections 4.4 and 4.8 of the SmPC to include information on autoimmune hepatitis and hepatic injury. The Package Leaflet has been updated accordingly. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH | 21/07/2011 | 18/08/2011 | SmPC and PL     | In December 2010, the MAH was requested by the CHMP to provide a review of the hepatic safety profile of ambrisentan. Following this request the MAH provided a cumulative review of relevant clinical trial data and spontaneous cases with hepatic adverse events that were assessed as FUM021. As a result of the review of the data provided it was concluded that there are no new concern but some additions in Sections 4.4 and 4.8 of the SmPC regarding autoimmune hepatitis and hepatic injury were recommended. With this type II variation MAH has applied to update sections 4.4 and 4.8 of the SmPC to include information on autoimmune hepatitis and hepatic injury. The Package Leaflet has been updated accordingly. |
| IB/0018 | C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH                                                                                                                                                                                                                                                                               | 04/07/2011 | n/a        | SmPC            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IA/0016 | A.5.a - Administrative change - Change in the name and/or address of a manufacturer responsible for batch release                                                                                                                                                                                                                                                                                                                                                                                                                        | 04/05/2011 | n/a        | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0014 | Upon request of the CHMP after assessment of 4th ambrisentan PSUR the MAH updated section 4.8 of the SmPC and Section 4 of the PIL to add new safety information relating to increase of hepatic transaminases. In addition, minor editorial changes have been made to SmPC and PL to adapt to QRD                                                                                                                                                                                                                                       | 20/01/2011 | 21/02/2011 | SmPC and PL     | Section 4.8 of the SmPC has been updated to add \"hepatic transaminases increased\" as an adverse drug reaction with a frequency of common, following the Guideline on the Summary of Product Characteristics (September 2009).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|           | version 7.3. - Changes (Safety/Efficacy) of Human and Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |     |          | template C.I.z Veterinary   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------|-----------------------------|
| IA/0015   | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 04/02/2011 | n/a |          |                             |
| IG/0034/G | This was an application for a group of variations. C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD C.I.9.g - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the site undertaking pharmacovigilance activities C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system | 06/01/2011 | n/a | Annex II |                             |

<div style=\"page-break-after: always\"></div>

|         | system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0012 | Update of Summary of Product Characteristics. Update of Summary of Product Characteristics                                                                                                                                                                                                                                   | 18/02/2010 | 23/03/2010 | SmPC        | Update of section 4.4 of the SPC to include a warning for Pulmonary veno occlusive disease (PVOD) to warn healthcare professionals of the risk of pulmonary oedema induced by vasodilating agents (i.e. endothelin receptor antagonists) in patients with PAH.                                                                                                                                                                                                                                                                                                                                  |
| II/0011 | Update of Summary of Product Characteristics and Package Leaflet. Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                           | 18/02/2010 | 23/03/2010 | SmPC and PL | Following the assessment of the 3rd PSUR, the MAH was requested to submit a type II variation to add the hypotension, syncope, nausea, vomiting, and diarrhoea to section 4.8 of the SPC as undesirable effects of unknown frequency. The Package leaflet is updated accordingly.                                                                                                                                                                                                                                                                                                               |
| II/0009 | Update of Summary of Product Characteristics and Package Leaflet. Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                           | 18/02/2010 | 23/03/2010 | SmPC and PL | Further to CHMP request based on the results of a drug- drug interaction study with rifampicin, sections 4.4 , 4.5 and 5.2 of the SPC are amended. Information of transient (approximately 2-fold) increase in ambrisentan exposure without clinically relevant effect on ambrisentan exposure is introduced in sections 4.5 interaction with other medicinal products and section 5.2 pharmacokinetic properties. In addition, a warning statement is added in section 4.4 to inform that patients on ambrisentan therapy should be closely monitored when starting treatment with rifampicin. |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                |            |            |             | The Package leaflet is updated accordingly. Other minor information concerning receptor binding is introduced in section 5.1 of the SPC . Furthermore, text and drawings are introduced in the package leaflet to provide instructions on how to open the child resistant blister packaging.                                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0010 | Update of the Detailed Description of the Pharmacovigilance System (DDPS) including change of the Qualified Person for Pharmacovigilance (QPPV). Consequently, Annex II has been updated with the new version number. Changes to QPPV Update of DDPS (Pharmacovigilance)                                                                                       | 17/12/2009 | 20/01/2010 | Annex II    | The DDPS has been updated (version 7.2) to reflect the change of the QPPV as well as to notify other changes to the DDPS performed since the last approved version. Consequently, Annex II has been updated using the standard text including the new version number of the agreed DDPS. The CHMP considers that the Pharmacovigilance System as described by the MAH fulfils the requirements.                                                                                                                                                                                                                                                                                                              |
| II/0008 | Update of Summary of Product Characteristics and Package Leaflet Update of sections 4.2, 4.5 and 5.2 of the Summary of Product Characteristics (SPC) further to the results of a drug-drug interaction study with cyclosporine A (FUM 001). The Package Leaflet has been updated accordingly. Update of Summary of Product Characteristics and Package Leaflet | 19/11/2009 | 21/12/2009 | SmPC and PL | At the time of the granting of the initial marketing authorisation, the Marketing Authorisation Holder (MAH) made the following commitment to perform a drug-drug interaction (DDI) study with cyclosporine (FUM 001). The MAH conducted a phase 1, open-label, parallel-design, single-center study to assess the effect of multiple dose administration of CsA on the steady-state PK of ambrisentan and its circulating metabolite, 4 hydroxymethyl ambrisentan and to assess the effect of multiple dose administration of ambrisentan on the steady- state PK of CsA in healthy subjects. Steady-state co-administration of ambrisentan and cyclosporine A resulted in a 2-fold increase in ambrisentan |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                        |            |            |                       | exposure in healthy volunteers. This may be due to the inhibition by cyclosporine A of transporters and metabolic enzymes involved in the pharmacokinetics of ambrisentan. Therefore the dose of ambrisentan should be limited to 5 mg once daily when co-administered with cyclosporine A and the patient should be carefully monitored. Multiple doses of ambrisentan had no effect on cyclosporine A exposure, and no dose adjustment of cyclosporine A is warranted. The Product information has been updated accordingly.                                                                                                      |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0006 | Update of Summary of Product Characteristics, Annex II and Package Leaflet Update of Summary of Product Characteristics, Labelling and Package Leaflet | 23/07/2009 | 28/08/2009 | SmPC, Annex II and PL | Update of section 4.8 of the Summary of the Product Characteristics (SPC) to add the adverse drug reactions pruritus, dizziness, chest pain and chest discomfort, further to the request of the CHMP following the assessment of the 1st PSUR. The Package Leaflet has been updated accordingly. The MAH also proposed minor changes to Sections 2 and 5.2 of the SPC, and to update the email address of the local representative in Denmark in Section 6 of the Package Leaflet. In addition, the MAH took the opportunity to update the version number of the Risk Management Plan in Annex II with the latest agreed version 3. |
| IA/0007 | IA_29_b_Change in qual./quant. composition of immediate packaging - all other pharm. forms                                                             | 28/04/2009 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0005 | Changes to QPPV Update of DDPS (Pharmacovigilance)                                                                                                     | 19/03/2009 | 07/04/2009 | Annex II              | Update of the Detailed Description of the Pharmacovigilance System (DDPS) and change of the Qualified Person for Pharmacovigilance (QPPV). Consequently, Annex II of the Product Information is                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                        | updated with the agreed version number of the DDPS (version 6.2). In addition, the MAH took the opportunity to update Annex II with the latest agreed version number of the Risk Management plan (version 3.0).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0004 | Update of Section 4.5 (Interaction with other medicinal products and other forms of interaction) and Section 5.2 (Pharmacokinetic properties) of the SPC based on the results of two new drug interaction studies with tadalafil and with an oral contraceptive pill, respectively. Update of Summary of Product Characteristics                                                                                                                                                                                        | 22/01/2009 | 26/02/2009 | SmPC                   | Two new pharmacokinetic drug interaction studies with tadalafil and with an oral contraceptive pill were submitted in this variation application. The results of the drug interaction study with tadalfil showed Co-administration of ambrisentan with tadalafil (phosphodiesterase inhibitor, substrate of CYP3A4) in healthy volunteers did not significantly affect the pharmacokinetics of either tadalafil or ambrisentan. In a clinical study in healthy volunteers, steady-state dosing with ambrisentan 10 mg once daily did not significantly affect the single-dose pharmacokinetics of the ethinyl estradiol and norethindrone components of a combined oral contraceptive. Based on this pharmacokinetic study, ambrisentan would not be expected to significantly affect exposure to oestrogen- or progestogen based contraceptives. |
| II/0003 | Update of sections 4.4 and 4.8 of the Summary of Product Characteristics (SPC) with regards to heart failure associated with fluid retention and worsening dyspnoea of unclear aetiology further to safety review conducted by the MAH during the preparation of the 1st PSUR. The Package Leaflet is proposed to be updated accordingly. Additionally, the MAH took the opportunity to make a minor editorial change to the ATC code in section 5.1, make a minor formatting update within section 5.2 and correct the | 18/12/2008 | 26/01/2009 | SmPC, Labelling and PL | Further to post-marketing reports of heart failure (with or without evidence of fluid retention) from spontaneous and clinical study sources, the MAH conducted a safety review of these events. The MAH has selected case reports of acute right ventricular failure, cardiac failure, cardiac failure congestive, left ventricular failure, right ventricular failure, ventricular failure, pulmonary oedema, and pulmonary congestion received up to 8th April 2008. There were a total of 122 reports. Of these 122 reports, 82 had associated fluid retention events (fluid retention, general                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | animal models quoted within section 5.3 of the SPC. Furthermore, the Marketing Authorisation Numbers and Date of First Authorisation have been added to the SPC and labelling where appropriate. Update of Summary of Product Characteristics, Labelling and Package Leaflet   |            |     | oedema, or peripheral oedema). Based on this review, the MAH proposed to include in section 4.8 of the SPC \"Cardiac failure (associated to fluid retention)\" as a cardiac adverse reaction identified through post-marketing surveillance and occurring with an unknown frequency. Additionally, the warning in section 4.4 was reworded to state that fluid retention shortly after starting ambrisentan may lead to decompensated heart failure and that pre-existing fluid overload should be managed prior to starting the drug. In addition, further to post-marketing reports of dyspnoea, in particular, reports of dyspnoea occurring shortly after starting ambrisentan therapy, the MAH has performed a cumulative review of reports of dyspnoea (dyspnoea, dyspnoea exertional, respiratory distress, asthma, hypoxia, and wheezing) identified up to 15 February 2008. A total of 108 cases of dyspnoea were retrieved. In 44 there was no information to assess time to onset. Among the remaining 64 cases, 32 involved a time to onset of ? 1 week, 10 had a time to onset > 1 week and ? 3 weeks, and 22 had a time to onset > 3 weeks. Regarding the 32 cases presented within the first week, all were spontaneous reports and 17 were medically confirmed. These cases provide some evidence of a causal association with ambrisentan. Based on this review, the MAH proposed to include   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0002 | IB_11_c_Change in batch size of active substance or intermediate - more than 10-fold                                                                                                                                                                                           | 30/05/2008 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| IB/0001   | IB_14_b_Change in manuf. of active substance without Ph. Eur. certificate - new manufacturer   | 20/05/2008   | n/a   |
|-----------|------------------------------------------------------------------------------------------------|--------------|-------|